All Stories

  1. Health Hazard Among Shrimp Cultivators in India: A Quantitative Burden of Disease Study
  2. Out-of-pocket pharmaceutical expenditure and its determinants among Iranian households with elderly members: a double-hurdle model
  3. Mobile money, medical cost anxiety and welfare of individuals within the reproductive age in Malaysia
  4. Reimagining the relationship between economics and health– WHO ‘Health for all’ provisions
  5. Population ageing and sustainability of healthcare financing in China
  6. Characteristics of Top-Searched Individuals in Japan’s Yen for Docs Conflicts of Interest Database During the COVID-19 Pandemic
  7. Global, regional, and national incidence of six major immune-mediated inflammatory diseases: findings from the global burden of disease study 2019
  8. Global, regional, and national burden of rheumatoid arthritis, 1990–2020, and projections to 2050: a systematic analysis of the Global Burden of Disease Study 2021
  9. Double burden of vulnerability for refugees: conceptualization and policy solutions for financial protection in Iran using systems thinking approach
  10. Hepatitis B and C in Europe: an update from the Global Burden of Disease Study 2019
  11. Successes and challenges of China’s health care reform: a four-decade perspective spanning 1985—2023
  12. Dynamics of Health Financing among the BRICS: A Literature Review
  13. Editorial: Current questions and challenges in healthcare of the post-socialist countries
  14. Global, regional, and national burden of meningitis and its aetiologies, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019
  15. Future health expenditure in the BRICS countries: a forecasting analysis for 2035
  16. Strategic management and organizational culture of medical device companies in relation to corporate performance
  17. Analyzing the Effectiveness of Data-Linked Projects for Health Promotion in Public Health Centers of South Korea
  18. Contemporary Universal Health Coverage in India – The Case of Federal State of Odisha (Orissa)
  19. Generic drug crisis in Japan and changes leading to the collapse of universal health insurance established in 1961: the case of Kobayashi Kako Co. Ltd.
  20. Fiscal Decentralization and the Human Development Index: A Cross-Border Empirical Study
  21. Partial Contribution of Socioeconomic Factors to the Mortality Rate of the Working-Age Population in Russia
  22. Global burden of chronic respiratory diseases and risk factors, 1990–2019: an update from the Global Burden of Disease Study 2019
  23. Editorial: Global population aging – Health care, social and economic consequences, volume II
  24. Editorial: Challenges of pharmacoeconomics in global health arena—Contemporary momentum in the early 2020s
  25. Corrigendum to “Utilisation Trend of Long-Acting Insulin Analogues including Biosimilars across Europe: Findings and Implications”
  26. Socioeconomic and Behavioral Determinants of Cardiovascular Risk in Russia: A Structural Equation Modeling Approach
  27. Editorial: Role of health economic data in policy making and reimbursement of new medical technologies, Volume II
  28. Editorial: Global excellence in health economics: Asia and Australasia
  29. Consequences of India’s population aging to its healthcare financing and provision
  30. Editorial: Asian health sector growth in the next decade—Optimism despite challenges ahead
  31. Sustainable Health Care Provision Worldwide: Is There a Necessary Trade-Off between Cost and Quality?
  32. The impact of transparency constraints on the efficiency of the Russian healthcare system: systematic literature review
  33. Global investments in pandemic preparedness and COVID-19: development assistance and domestic spending on health between 1990 and 2026
  34. Healthcare system development in the Middle East and North Africa region: Challenges, endeavors and prospective opportunities
  35. Mapping age- and sex-specific HIV prevalence in adults in sub-Saharan Africa, 2000–2018
  36. Comparison of the healthcare system of Chile and Brazil: strengths, inefficiencies, and expenditures
  37. Editorial: Does healthcare financing explain different healthcare system performances and responses to COVID-19?
  38. Global mortality associated with 33 bacterial pathogens in 2019: a systematic analysis for the Global Burden of Disease Study 2019
  39. The global, regional, and national burden of benign prostatic hyperplasia in 204 countries and territories from 2000 to 2019: a systematic analysis for the Global Burden of Disease Study 2019
  40. Editorial: Health care financing and affordability in the emerging global markets, Volume II
  41. Editorial: Big data shaping clinical trial landscape—Greater role for pharmacoeconomics in Asia
  42. Solid Fuel Use and Health in Developing Countries
  43. Assessing performance of the Healthcare Access and Quality Index, overall and by select age groups, for 204 countries and territories, 1990–2019: a systematic analysis from the Global Burden of Disease Study 2019
  44. The quality of Syrian healthcare services during COVID-19: A HEALTHQUAL approach
  45. Editorial: Inequality in healthcare utilization and household spending in developing countries
  46. Editorial: Insights in health economics: 2021
  47. Estimates, trends, and drivers of the global burden of type 2 diabetes attributable to PM2·5 air pollution, 1990–2019: an analysis of data from the Global Burden of Disease Study 2019
  48. Environmental Pollution Liability Insurance of Health Risk and Corporate Environmental Performance: Evidence From China
  49. Global article collection: essential reads from around the world
  50. Systematic Review of Existing Stroke Guidelines: Case for a Change
  51. Gap analysis in manufacturing, innovation and marketing of medical devices in the Asia-Pacific region
  52. Adolescent transport and unintentional injuries: a systematic analysis using the Global Burden of Disease Study 2019
  53. Editorial: Fraud and Corruption in Healthcare
  54. Methods for Improving the Variance Estimator of the Kaplan–Meier Survival Function, When There Is No, Moderate and Heavy Censoring-Applied in Oncological Datasets
  55. The burden of injury in Central, Eastern, and Western European sub-region: a systematic analysis from the Global Burden of Disease 2019 Study
  56. Editorial: Emerging Markets’ Health and Pharmaceutical Sectors at the Dawn of a Potential Global Financial Crisis of early 2020s
  57. Global, regional, and national burden of colorectal cancer and its risk factors, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019
  58. How China controls the Covid-19 epidemic through public health expenditure and policy?
  59. Correction to: Future health spending forecast in leading emerging BRICS markets in 2030: health policy implications
  60. Global, regional, and national burden of diseases and injuries for adults 70 years and older: systematic analysis for the Global Burden of Disease 2019 Study
  61. Future health spending forecast in leading emerging BRICS markets in 2030: health policy implications
  62. Predictors of loss due to pharmaceutical fraud: evidence from the U.S.
  63. Prevalence of COVID-19 Pandemic, Self-Esteem and Its Effect on Depression Among University Students in Saudi Arabia
  64. How Fast Are the Asian Countries Progressing Toward Green Economy? Implications for Public Health
  65. Disempowered Mothers Have Undernourished Children: How Strong Is the Intrinsic Agency?
  66. The burden of injury in Central, Eastern, and Western European sub-region: a systematic analysis from the Global Burden of Disease 2019 Study
  67. Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life Years for 29 Cancer Groups From 2010 to 2019
  68. Editorial: Health Financing and Spending in Low- and Middle-Income Countries
  69. Asian innovation in pharmaceutical and medical device industry – beyond tomorrow
  70. The Global South political economy of health financing and spending landscape – history and presence
  71. Therapeutic innovations: the future of health economics and outcomes research – increasing role of the Asia-Pacific
  72. Editorial: Universal Health Coverage: The Long Road Ahead for Low- and Middle-Income Regions
  73. A Proactive Approach to Identify the Exposure Risk to COVID-19: Validation of the Pandemic Risk Exposure Measurement (PREM) Model Using Real-World Data
  74. Utilisation Trend of Long-Acting Insulin Analogues including Biosimilars across Europe: Findings and Implications
  75. Sustainability Challenge of Eastern Europe—Historical Legacy, Belt and Road Initiative, Population Aging and Migration
  76. Mapping Anemia in Women: Global Trends and Inequality
  77. Global, regional, and national mortality among young people aged 10–24 years, 1950–2019: a systematic analysis for the Global Burden of Disease Study 2019
  78. Tracking development assistance for health and for COVID-19
  79. COVID-19 Vaccine, TRIPS, and Global Health Diplomacy: India’s Role at the WTO Platform
  80. Sustainability Challenge of Eastern Europe - Historical Legacy, Belt and Road Initiative, Population Ageing and Migration
  81. Predictors of Loss Due to Pharmaceutical Fraud: Evidence From the U.S.
  82. COVID-19 Pandemic: An Opportunity for Universal Health Coverage
  83. Future Health Spending Forecast in Leading Emerging BRICS Markets in 2030 - Health Policy Implications
  84. Happiness: A Novel Outcome Measure in Stroke?
  85. Current utilisation patterns for long-acting insulin analogues including biosimilars among selected Asian countries and the implications for the future
  86. The Current Situation Regarding Long-Acting Insulin Analogues Including Biosimilars Among African, Asian, European, and South American Countries; Findings and Implications for the Future
  87. Editorial: NCDs – Core Challenge of Modern Day Health Care Establishments
  88. Analysis and Forecasting Incidence, Intensive Care Unit Admissions, and Projected Mortality Attributable to COVID-19 in Portugal, the UK, Germany, Italy, and France: Predictions for 4 Weeks Ahead
  89. Editorial: Accelerated Globalization and Its Impact to the World's Health Care Achievement
  90. Subnational mapping of HIV incidence and mortality among individuals aged 15–49 years in sub-Saharan Africa, 2000–18: a modelling study
  91. Spatial, temporal, and demographic patterns in prevalence of smoking tobacco use and attributable disease burden in 204 countries and territories, 1990–2019: a systematic analysis from the Global Burden of Disease Study 2019
  92. Forecasted Incidence, Intensive Care Unit Admissions and Projected Mortality Attributable to Covid-19 in Portugal, UK, Germany, Italy and France – 4 Weeks Ahead
  93. Spatial, temporal, and demographic patterns in prevalence of chewing tobacco use in 204 countries and territories, 1990–2019: a systematic analysis from the Global Burden of Disease Study 2019
  94. Highlighting the Role of Universally Available and Innate Immune Cell Counts in Acute Ischemic Stroke: A Scoping Review
  95. Public Health Policy of India and COVID-19: Diagnosis and Prognosis of the Combating Response
  96. Cost Analysis of Health Examination Screening Program for Ischemic Heart Disease in Active-Duty Military Personnel in the Middle-Income Country
  97. Elevated Neutrophil to Lymphocyte Ratio Predicts In-hospital Mortality Among Stroke Patients in a Metropolitan hospital in Australia, Universal Value-added measure in Stroke Care
  98. Scoping Review of Existing Stroke Guidelines; Argument for a Value-Added Change<strong> </strong>
  99. Scoping Review of Existing Stroke Guidelines; Argument for a Value-Added Change
  100. Demographic forecasting of population aging in Greece and Cyprus: one big challenge for the Mediterranean health and social system long-term sustainability
  101. Universally Available Innate and Adaptive Immune Cell Counts in Acute Ischemic Stroke (AIS) in the Context of Shared Pathobiology with COVID-19; Scoping Review
  102. Sanitary and Hygienic Aspects of the COVID-19 Self-isolation
  103. Mapping routine measles vaccination in low- and middle-income countries
  104. Corona-Triggered Global Macroeconomic Crisis of the Early 2020s
  105. Organizational measures aiming to combat COVID-19 in the Russian Federation: the first experience
  106. Five insights from the Global Burden of Disease Study 2019
  107. Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019
  108. Global burden of 87 risk factors in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019
  109. <p>A Country Pandemic Risk Exposure Measurement Model</p>
  110. <p>Predictors of (in)efficiencies of Healthcare Expenditure Among the Leading Asian Economies – Comparison of OECD and Non-OECD Nations</p>
  111. Gross Domestic Product and Health Expenditure Growth in Balkan and East European Countries—Three-Decade Horizon
  112. Mapping geographical inequalities in access to drinking water and sanitation facilities in low-income and middle-income countries, 2000–17
  113. Estimating global injuries morbidity and mortality: methods and data used in the Global Burden of Disease 2017 study
  114. Fraudster’s and victims’ profiles and loss predictors’ hierarchy in the mental healthcare industry in the US
  115. Mapping geographical inequalities in oral rehydration therapy coverage in low-income and middle-income countries, 2000–17
  116. Measuring universal health coverage based on an index of effective coverage of health services in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019
  117. Real GDP growth rates and healthcare spending – comparison between the G7 and the EM7 countries
  118. Author Correction: Mapping local patterns of childhood overweight and wasting in low- and middle-income countries between 2000 and 2017
  119. Promises and Hurdles of Medical Tourism Development in the Russian Federation
  120. Mapping geographical inequalities in childhood diarrhoeal morbidity and mortality in low-income and middle-income countries, 2000–17: analysis for the Global Burden of Disease Study 2017
  121. Prevalence and attributable health burden of chronic respiratory diseases, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017
  122. Global injury morbidity and mortality from 1990 to 2017: results from the Global Burden of Disease Study 2017
  123. Mapping local patterns of childhood overweight and wasting in low- and middle-income countries between 2000 and 2017
  124. Cost-effectiveness and resource allocation (CERA) 18 years of evolution: maturity of adulthood and promise beyond tomorrow
  125. Health sector spending and spending on HIV/AIDS, tuberculosis, and malaria, and development assistance for health: progress towards Sustainable Development Goal 3
  126. Changes in disease burden in Poland between 1990–2017 in comparison with other Central European countries: A systematic analysis for the Global Burden of Disease Study 2017
  127. A Correlation Study of the Colorectal Cancer Statistics and Economic Indicators in Selected Balkan Countries
  128. Alcohol Consumption among the Elderly Citizens in Hungary and Serbia—Comparative Assessment
  129. GBD 2016. Occupational Carcinogens Collaborators
  130. Global and regional burden of chronic respiratory disease in 2016 arising from non-infectious airborne occupational exposures: a systematic analysis for the Global Burden of Disease Study 2016
  131. Global and regional burden of disease and injury in 2016 arising from occupational exposures: a systematic analysis for the Global Burden of Disease Study 2016
  132. The Evaluation of Antibiotic Consumption at the Inpatient Level in Kazakhstan from 2011 to 2018
  133. Structural Factors Responsible for Universal Health Coverage in Low- and Middle-Income Countries: Results From 118 Countries
  134. Burden of injury along the development spectrum: associations between the Socio-demographic Index and disability-adjusted life year estimates from the Global Burden of Disease Study 2017
  135. Morbidity and mortality from road injuries: results from the Global Burden of Disease Study 2017
  136. Real GDP growth rates and health care spending – Comparison between the G7 and the EM7 countries
  137. Mapping child growth failure across low- and middle-income countries
  138. Mapping disparities in education across low- and middle-income countries
  139. Dynamics of Health Care Financing and Spending in Serbia in the XXI Century
  140. The global, regional, and national burden of colorectal cancer and its attributable risk factors in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017
  141. The Impact of the Socio-Demographic Characteristics of Complementary and Alternative Medicine Users in Serbia on OTC Drug Consumption
  142. Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2017
  143. Situation, Impacts, and Future Challenges of Tobacco Control Policies for Youth: An Explorative Systematic Policy Review
  144. The impact of health expenditures on public health in BRICS nations
  145. Underlying Differences in Health Spending Within the World Health Organisation Europe Region—Comparing EU15, EU Post-2004, CIS, EU Candidate, and CARINFONET Countries
  146. Past, present, and future of global health financing: a review of development assistance, government, out-of-pocket, and other private spending on health for 195 countries, 1995–2050
  147. Analysis of the Financing of Russian Health Care over the Past 100 Years
  148. Medical Cost of Colorectal Cancer Services in Serbia Between 2014 and 2017: National Data Report
  149. Global, regional, and national burden of neurological disorders, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016
  150. Comparative financing analysis and political economy of noncommunicable diseases
  151. Global, regional, and national burden of suicide mortality 1990 to 2016: systematic analysis for the Global Burden of Disease Study 2016
  152. Global, regional, and national burden of brain and other CNS cancer, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016
  153. Global, regional, and national burden of epilepsy, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016
  154. Global, regional, and national burden of traumatic brain injury and spinal cord injury, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016
  155. Editorial: Challenges of Pharmacoeconomics in Global Health Arena
  156. Editorial: Global Population Aging - Health Care, Social and Economic Consequences
  157. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980–2017: a systematic analysis for the Global Burden of Disease Study 2017
  158. Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease ...
  159. Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017
  160. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017
  161. Measuring progress of the health-related Sustainable Development Goals for 195 countries
  162. Global, regional, and national age-sex-specific mortality and life expectancy, 1950–2017: a systematic analysis for the Global Burden of Disease Study 2017
  163. Population and fertility by age and sex for 195 countries and territories, 1950–2017: a systematic analysis for the Global Burden of Disease Study 2017
  164. Estimates of the global, regional, and national morbidity, mortality, and aetiologies of lower respiratory infections in 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016
  165. Department of Error
  166. Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2016
  167. The Influence of Universal Health Coverage on Life Expectancy at Birth (LEAB) and Healthy Life Expectancy (HALE): A Multi-Country Cross-Sectional Study
  168. Global Burden of Multiple Myeloma
  169. Global Mortality From Firearms, 1990-2016
  170. Cold War Legacy in Public and Private Health Spending in Europe
  171. High Inequalities Associated With Socioeconomic Deprivation in Cardiovascular Disease Burden and Antihypertensive Medication in Hungary
  172. Antibiotic Resistance in Syria: A Local Problem Turns Into a Global Threat
  173. Alcohol use and attributable disease burden in 195
  174. The burden of disease in Greece, health loss, risk factors, and health financing, 2000–16: an analysis of the Global Burden of Disease Study 2016
  175. Measuring performance_Healthcare Access_Quality Index for 195 countries and territories
  176. Access to orphan drugs – comparison across Balkan countries
  177. High Out-of-Pocket Health Spending in Countries With a Mediterranean Connection
  178. Population aging and migration – history and UN forecasts in the EU-28 and its east and south near neighborhood – one century perspective 1950–2050
  179. Budgetary Impact of Medicinal Therapies for Rare Diseases in Bulgaria
  180. Global, regional, and national burden of neurological disorders during 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015
  181. Transposition and implementation of EU rare disease policy in Eastern Europe
  182. Department of Error
  183. Editorial: Role of Health Economic Data in Policy Making and Reimbursement of New Medical Technologies
  184. RESILIENCE, PSYCHIATRY AND RELIGION FROM PUBLIC AND GLOBAL MENTAL HEALTH PERSPECTIVE Dialogue and Cooperation in the Search for Humanistic Self, Compassionate Society and Empathic Civilization
  185. Measuring progress and projecting attainment on the basis of past trends of the health-related Sustainable Development Goals in 188 countries: an analysis from the Global Burden of Disease Study 2016
  186. Global, regional, and national age-sex specific mortality for 264 causes of death, 1980–2016: a systematic analysis for the Global Burden of Disease Study 2016
  187. Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016
  188. Global, regional, and national disability-adjusted life-years (DALYs) for 333 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016
  189. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016
  190. Global, regional, and national under-5 mortality, adult mortality, age-specific mortality, and life expectancy, 1970–2016: a systematic analysis for the Global Burden of Disease Study 2016
  191. Global, regional, and national deaths, prevalence, disability-adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015
  192. Department of Error
  193. Growth of Global Publishing Output of Health Economics in the Twenty-First Century: A Bibliographic Insight
  194. Maternal mortality and morbidity burden in the Eastern Mediterranean Region: findings from the Global Burden of Disease 2015 study
  195. The burden of mental disorders in the Eastern Mediterranean region, 1990–2015: findings from the global burden of disease 2015 study
  196. Burden of cancer in the Eastern Mediterranean Region, 2005–2015: findings from the Global Burden of Disease 2015 Study
  197. Healthcare Access and Quality Index based on mortality from causes amenable to personal health care in 195 countries and territories, 1990–2015: a novel analysis from the Global Burden of Disease Study 2015
  198. Pharmaceutical expenditure dynamics in the Balkan countries
  199. Child and Adolescent Health From 1990 to 2015
  200. Alcohol Beverage Household Expenditure, Taxation and Government Revenues in Broader European WHO Region
  201. Evolution and patterns of global health financing 1995–2014: development assistance for health, and government, prepaid private, and out-of-pocket health spending in 184 countries
  202. Future and potential spending on health 2015–40: development assistance for health, and government, prepaid private, and out-of-pocket health spending in 184 countries
  203. Disability, Work Absenteeism, Sickness Benefits, and Cancer in Selected European OECD Countries—Forecasts to 2020
  204. Satisfaction with Health Services among the Citizens of Serbia
  205. Commentary: Do health care workforce, population, and service provision significantly contribute to the total health expenditure? An econometric analysis of Serbia
  206. Within the triangle of healthcare legacies: comparing the performance of South-Eastern European health systems
  207. Population ageing alongside health care spending growth
  208. Department of Error
  209. Global, Regional, and National Levels of Maternal Mortality, 1990–2015
  210. Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-years for 32 Cancer Groups, 1990 to 2015
  211. Caffeine consumption patterns and determinants among adolescents in Serbia
  212. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015
  213. Global, regional, and national levels of maternal mortality, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015
  214. Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015
  215. Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015
  216. Direct Medical Costs Of Treating Colorectal Cancer Patients With Different Chemotherapy Protocols Regarding Stage And Outcome Of The Disease
  217. Evolving Health Expenditure Landscape of the BRICS Nations and Projections to 2025
  218. Capitation-Based Financing Hampers the Provision of Preventive Services in Primary Health Care
  219. Measuring the health-related Sustainable Development Goals in 188 countries: a baseline analysis from the Global Burden of Disease Study 2015
  220. Correction to Lancet HIV 2016; 3: e361–87
  221. Commentary: Implementing Pro-Poor Universal Health Coverage
  222. Estimates of global, regional, and national incidence, prevalence, and mortality of HIV, 1980–2015: the Global Burden of Disease Study 2015
  223. Health Economics at the Crossroads of Centuries – From the Past to the Future
  224. Self-Assessed Health and Socioeconomic Inequalities in Serbia: Data from 2013 National Health Survey
  225. Review of Diagnosis-Related Group-Based Financing of Hospital Care
  226. Commentary: Patient Cost Sharing and Medical Expenditures for the Elderly
  227. Long Term Dental Work Force Build-Up and DMFT-12 Improvement in the European Region
  228. Growth of Global Health Spending Share in Low and Middle Income Countries
  229. Do Health Reforms Impact Cost Consciousness of Health Care Professionals? Results from a Nation-Wide Survey in the Balkans
  230. The New and Old Europe: East-West Split in Pharmaceutical Spending
  231. Editorial: Health Care Financing and Affordability in the Emerging Global Markets
  232. CYP1A2 genotype affects carbamazepine pharmacokinetics in children with epilepsy
  233. Health Care Financing and Affordability in the Emerging Global Markets
  234. The aging of Europe. The unexplored potential
  235. Life expectancy and health expenditure evolution in Eastern Europe—DiD and DEA analysis
  236. Comparison of historical medical spending patterns among the BRICS and G7
  237. Regulatory Issues Surrounding Audit of Electronic Cigarette Charge Composition
  238. When cure becomes an illness—abuse of addictive prescription medicines
  239. Budget Impact of Publicly Reimbursed Prescription Medicines in the Republic of Srpska
  240. Improvements in Neonatal and Childhood Medical Care – Perspective from the Balkans
  241. Five-year survival and costs of care in metastatic colorectal cancer: conventional versus monoclonal antibody-based treatment protocols
  242. BRIC’s Growing Share of Global Health Spending and Their Diverging Pathways
  243. Growing Burden of Non-Communicable Diseases in the Emerging Health Markets: The Case of BRICS
  244. Hospital oncology costs among the cohort of elderly in an aging South-Eastern European nation
  245. Cost differentials of dental outpatient care across clinical dentistry branches
  246. Community-acquired pneumonia: economics of inpatient medical care vis-à-vis clinical severity,
  247. Evolution of the Serbian pharmaceutical market alongside socioeconomic transition
  248. Accessibility and Affordability of Alcohol Dependency Medical Care in Serbia
  249. Can Didactic Continuing Education Improve Clinical Decision Making and Reduce Cost of Quality? Evidence From a Case Study
  250. Macroeconomic Policy Impact On Oncology-Related Public Expenditure In An Emerging European Market – Signs Of Early Recovery
  251. Structural validity and reliability of the healthcare professionals' economic reasoning questionnaire
  252. End-of-life costs of medical care for advanced stage cancer patients
  253. Health Financing Constrained by Population Aging - An Opportunity to Learn from Japanese Experience / Finansiranje Zdravstvene Zaštite U Uslovima Starenja Popualcije - Prilika Da Učimo Na Japanskom Iskustvu
  254. LAT Software Induced Savings on Medical Costs of Alcohol Addicts' Care - Results from a Matched-Pairs Case-Control Study
  255. Intentional Self-Poisonings and Unintentional Poisonings of Adolescents With Nonfatal Outcomes
  256. Cost Comparison Among First Line Monoclonal Antibodies-Based Oncology Treatment Protocols
  257. Costs of Dental Outpatient Care – Resource Use Differentials Across Clinical Dentistry Branches
  258. 10th World IHEA and ECHE joint congress: Health Economics in the Age of Longevity
  259. Radiation therapy remains the key cost driver of oncology inpatient treatment
  260. Oncology monoclonal antibodies expenditure trends and reimbursement projections in the emerging Balkan market
  261. Contemporary generic market in Japan – key conditions to successful evolution
  262. Health expenditure dynamics in Serbia 1995-2012
  263. 10.5937/mckg48-5071 = Recent developments in the world's leading generic markets
  264. The Key Role of the Leading Emerging Bric Markets in the Future of Global Health Care
  265. The key role of the leading emerging BRIC markets in the future of global health care
  266. Radiology Services Costs and Utilization Patterns Estimates in Southeastern Europe—A Retrospective Analysis from Serbia
  267. Cost-Utility Analysis of Depot Atypical Antipsychotics for Chronic Schizophrenia in Croatia
  268. Cross-sectional survey on complementary and alternative medicine awareness among health care professionals and students using CHBQ questionnaire in a Balkan country
  269. Craniocerebral injuries in traffic accidents with fatal outcomes
  270. Assessment of Viral Genotype Impact to the Cost-Effectiveness and Overall Costs of Care for Peg-Interferon-2α + Ribavirine Treated Chronic Hepatitis C Patients
  271. FARMAKOLOŠKI IN VITRO MODELI ZA PREDKLINIČKO ISPITIVANJE LEKOVA - PRIMER hSERT TRANSFICIRANIH HUMANIH EMBRIONALNIH ĆELIJA BUBREGA
  272. Serbian and Austrian Alcohol-Dependent Patients: A Comparison of Two Samples Regarding Therapeutically Relevant Clinical Features
  273. Resource allocation strategies in Southeastern European health policy
  274. Validation of a patient satisfaction questionnaire in primary health care
  275. Role of anticonvulsant therapeutic drug monitoring in improving clinical outcomes: An example of 12 adult epilepsy patients
  276. Estimate of clinical outcomes from the patient perspective is important for clinical decision making
  277. Blood alcohol concentration impact on the traffic accident rates with fatal outcome
  278. Analysis of toxicity and tolerance of contrast agents in conventional, CT and MR
  279. Inpatient Detoxification Procedure and Facilities: Financing Considerations from an Eastern European Perspective
  280. Current efforts and proposals to reduce healthcare costs in Serbia
  281. Economics of cancer related medical care: Worldwide estimates and available domestic evidence
  282. A Nonlinear Mixed Effects Modelling Analysis of Topiramate Pharmacokinetics in Patients with Epilepsy
  283. Assessment of diabetes mellitus type 2 treatment costs in the Republic of Serbia
  284. Current clinical evidence on topiramate pharmacokinetics
  285. Inverse correlation of valproic acid serum concentrations and quality of life in adolescents with epilepsy
  286. Cost-Effectiveness of Ritodrine and Fenoterol for Treatment of Preterm Labor in a Low–Middle-Income Country: A Case Study
  287. Effect of exogenous glutamate and N-Methyl-D-aspartic acid on spontaneous activity of isolated human ureter
  288. Inhibitory effects of selected antiepileptics on spontaneous motility of isolated human oviducts